We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

Rank Sector Weight
1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FCFS icon
201
FirstCash
FCFS
$9.49B
– –
-1,794
Closed -$216K
FCNCA icon
202
First Citizens BancShares
FCNCA
$25B
– –
-360
Closed -$667K
FHN icon
203
First Horizon
FHN
$12.1B
– –
-20,934
Closed -$407K
GDRX icon
204
GoodRx Holdings
GDRX
$1.06B
– –
-101,755
Closed -$449K
GOSS icon
205
Gossamer Bio
GOSS
$83.3M
– –
-61,984
Closed -$67.6K
GPK icon
206
Graphic Packaging
GPK
$3.29B
– –
-8,966
Closed -$233K
IBOC icon
207
International Bancshares
IBOC
$4.84B
– –
-14,953
Closed -$943K
IMUX icon
208
CALL
Immunic
IMUX
$205M
– –
-73
Closed -$5.5K
INDB icon
209
Independent Bank
INDB
$4.21B
– –
-5,382
Closed -$337K
IWM icon
210
PUT
iShares Russell 2000 ETF
IWM
$82.2B
– –
-238
Closed -$1.43K
KALV
211
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-241
Closed -$32.5K
KALV
212
DELISTED
KalVista Pharmaceuticals
KALV
– –
-34,098
Closed -$393K
KRE icon
213
CALL
State Street SPDR S&P Regional Banking ETF
KRE
$4.97B
– –
-1,520
Closed -$47.1K
KROS icon
214
CALL
Keros Therapeutics
KROS
$210M
– –
-354
Closed -$10.8K
KROS icon
215
PUT
Keros Therapeutics
KROS
$210M
– –
-153
Closed -$381K
HAPN
216
Happen Inc
HAPN
$2.27B
– –
-119,628
Closed -$1.23M
LDI icon
217
loanDepot
LDI
$607M
– –
-122,159
Closed -$145K
LXRX icon
218
CALL
Lexicon Pharmaceuticals
LXRX
$995M
– –
-3
Closed -$10
MCK icon
219
McKesson
MCK
$98.5B
– –
-2,628
Closed -$1.77M
MODV
220
DELISTED
ModivCare
MODV
– –
-8,757
Closed -$11.5K
MREO
221
Mereo BioPharma
MREO
$51.5M
– –
-113,247
Closed -$273K
NVO
222
Novo Nordisk
NVO
$228B
– –
-5,859
Closed -$399K
NVO
223
PUT
Novo Nordisk
NVO
$228B
– –
-287
Closed -$122K
PCVX icon
224
PUT
Vaxcyte
PCVX
$8.09B
– –
-119
Closed -$335K
QURE icon
225
uniQure
QURE
$2.71B
– –
-8,386
Closed -$113K
7 8
9
10 11

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.